Electronic Health Record Strategies for Pay for Performance







James O'Connor MD Director of Clinical Informatics





Early Days of EMR...



Access to Records

Template-based documentation



E&M Coding

Electronic Prescribing

EMR Dream has grown up!



Value of EHR in Physician's Practice



- Multi-year study of Physician Practices with EHR showed*:
 - Systems were completely paid for including hardware and training costs in 2.5 years
 - Each physician following the initial period of capital investment recovery earned on average \$23,000 per year after all maintenance costs.
 - Savings achieved by revenue increase (reduced undercoding of E&M service levels) and efficiency benefits (less transcription costs and less medical record staff)
- Single Practice Study showed \$30k reduction in transcription costs in the first 8 months of EHR use[§]
 - > Only *3 of 6* orthopedic surgeons using template documentation.
 - Many practices achieve 80 to 90% transcription saving after full implementation.

*HEALTH AFFAIRS ~ 2005 Volume 24 , #5

§Sports Med Arthosc Review ~2004;12:238-45



Pay for Performance: the next challenge for EHR systems

Do you want to be....



- Pay for Performance (P4P) represents a sea change in how physicians will be reimbursed.
 - This will be at least as significant as introduction of E&M documentation standards in 1985.
 - Concept is straight forward on the surface: Increased compensation is given to physicians who either report quality data and/or show that they meet pre-defined standards.
- The EHR is the main tool for successful capture of the clinical data needed for this type of reporting.
 - Unless the clinical data is captured at the point of care, the burden of retrospectively collecting it would deeply cut into any financial gains.
 - The right EHR system will allow a practice to establish a workflow which assists the physicians in providing efficient patient care while capturing quality data as a byproduct of patient visits.





Performance Measures: Examples



- Asthma/Respiratory Illness
 - Asthma: Assessment
 - > Asthma: Pharmacologic therapy



- Appropriate treatment for children with upper respiratory infection
- Appropriate testing for children with pharyngitis
- Behavioral Health/Depression
 - Optimal practitioner contacts for medication management
 - Effective acute phase treatment
 - Effective continuation phase treatment

Performance Measures: Examples

- Diabetes
 - HbA1c Management
 - Foot Exam
 - Microalbuminuria test
- Coronary Artery Disease
 - Symptoms and Activity
 - Lipid Monitoring and Treatment
 - Anti-platelet therapy
- Heart Failure
 - Left ventricular function (LVF) assessment
 - Assessment of symptoms/signs of fluid overload
 - > Warfarin therapy for patients with atrial fibrillation

Diabetes Epidemic Could Claim 622,000 Lives Annually by 2025

Changing diabetes program to stimulate system-wide change to combat disease

Nov. 9, 2005 - A new report released today by the Yale Schools of Public Health and Medicine in conjunction with the Institute for Alternative Futures reveals that if the healthcare system in the United States continues to fail in adequately preventing and treating diabetes, by the year 2025 the number of people dying and suffering from diabetes and its complications will roughly triple.

Getting from Performance Measure to P4P Reporting

Physician Consortium for Performance Improvement Adult Diabetes Core Physician Performance Measurement Set^a

	Clinical Recommendations/ Treatment Goals	Clinical Performance Measures Per Reporting Year			
A1c Management	A glycosylated hemoglobin (A1c) is recommended during an initial assessment and during follow-up assessmerts. ^{A11} (Level-E Evidence) ¹¹ Treatment Goals: AACE/ACE: A1c $\leq 6.5\%^{\circ}$ ADA: A1c $\leq 7\%^{11}$	Percentage of patients who received one or more A1c test(s) Numerator = Patients who received one or more A1c test(s) Denominator = AII patients diagnosed with diabetes			
		Per Patient: Number of A1c tests received Trend of A1c values	Per Patient Population: Percentage of patients who received one or more A1c test(s) Distribution of number of tests done (0, 1, 2, 3 or more) Distribution of most recent A1c value by range: <6.0%, 6.0-6.9%, 7.0-7.9%, 8.0-8.9%, 9.0-8.9%, ≥10%, undocumented		
Lipid Management	A fasting lipid profile is recommended during an initial assessment and during follow-up assessments. ^{16,10}	Percentage of patients who received at least one lipid profile (or ALL component tests) Numerator = Patients who received at least one lipid profile (or ALL component tests) Denominator = All patients diagnosed with diabetes			
	(Level-E Evidence)" Treatment Goals: NCEP#: Total cholesterol <200 mg/dl LDL cholesterol <100 mg/dl Triglycerides <150 mg/dl	Per Patient: Trend of values for each test	Per Patient Population: Percentage of patients who received at least one lipid profile (or ALL component tests) Distribution of most recent test values by range (mg'd): Total cholesterol: ≥240, 200-239, <200, undocumented LDL cholesterol: ≥160, 130-159, 100-129, <100, undocumented HDL cholesterol: <40, 40-49, 50-59, ≥60, undocumented Triglycerides: ≥400, 200-399, <200, 150-199, <150, undocumented		

Performance Measure for Diabetes

Patient Care via EHR System

P4P Report on HbA1c Outcomes

From Performance Measure to P4P emdeon^{**} Reporting: Needs Right EHR and Planning (Not Magic and Hope)

Care Guidelines: Primary Care and Adult Medicine 🔻

Pri	△ Reminder	Frequency	Status
2	Asthma Symptom Monitoringgeneral	q3months	Overdue
2	Recent ER Visit	q3months	Overdue
2	Asthma Action Plan	q3months	Overdue
2	Asthma Symptom Monitoringnocturnal	q3months	Due
2	Physical Tolerance Decreased	q3months	Due
2	Beta-2 Agonist Inhaler	q3months	Due
2	Problem Drinking Screening	q2yr	Due
2	Pap Smear Screening	q3yr	Due
2	Depression Screening	qyear	Due

Efficient and Informative Patient Care

Patient Care via EHR System

DM-02_HbA1c Mgmt Poor Control

Diabetic Patients (Tot DM Patients with HhA1c >

Structured Clinical Data as byproduct of **Patient Visits**

EHR Health Management Guidelines: View from the Clinic...

View:	Reminders Due 📃
Remina	der Orders
Reminder	Order
Beta-2 Ag	gonist Inhaler (q3months)
Pap Sme	Albuterol Sulfate 108 MCG/ACT AERS ar Screening (g3yr)
	Cytology: Pap Smear

Intergy EHR Health Management: Innovation in Disease Management

n

Physician Consortium for Performance Improvement Adult Diabetes Core Physician Performance Measurement Set®

	Clinical Recommendations/ Treatment Goals	Clinical Performance Measur	es Per Reporting Year		Form: FPMULTI_DX	<u>r</u>
Foot Examina Denominator Patients with bi amputation	A foot exam—visual inspection, sensory exam, and pulse exam—is recommended during an initial assessment and during follow-up assessments. ^{Q14}	Percentage of patients who rece sensory exam with monofilament Numerator = Patients who receive exam with monofilament, and pulse Denominator = All patients diagno	ived at least one comple ; and pulse exam) d at least one complete f e exam) sed with diabetes	ete foot exam (visual inspe oot exam (visual inspection,	Preview DM HPI HTN_Lipid HPI PM Diabetic Foot Exam-Monofi TV V N Decreased to VV N Decreased to	H ROS ROS 2 ROS 3 PE 1 ament Test (Sensation) ctile sensation-Right ctile sensation-Left
	in it is clic standard		9	ata capture Via Form	Diabetic Foot Exam-Inspect I Y IV N Right Foot App I Y IV N Left Foot App Diabetic Foot Exam-Pulses I Y IV N Dorsalis Pedi I Y IV N Dorsalis Pedi	on
Pri			Status		R	P2
🖃 Diabetes ((8 items)		. 505/00		hic	Ŧ
2	Foot Exam	q3months	Overdue			
2	Aspirin Use	daily	Due	Diabet	tic Foot Exam	
2	Assess Tobacco Use	q2yr	Due	Study n	eriod: 10/01/2004	- 09/30/2005
2	Blood Pressure Measurement	q3months	Due	orgel b.	51153. 1010 H2004	0010012000
2	Eye Exam by Ophthalmologist	qyear	Due	0		4000
2	Hemoglobin A1c	q3months	Due	Sum:Di	abetics	1866
2	Lipid Panel	q3months	Due	Sum:Dia	abetics_foot exam	1645
2	Urine Protein Screening (microalbumin)	qyear	Due	Percent	Diabetics foot ex	am 88.2%

emdeon^{**} EHR: Capture of Structured Data

Active Medications	△ Dosage	Days Left	Issued
Hydrochlorothiazide 25 MG TARS	ad 20 days -2 rofile	90 Dave Left	04/08/03
Lipitor 20 MG TA	Modicati	one	04/08/03
Metformin HCI 50	MEdicali	5115	04/08/03

Lab Tests 🛛 Description Status				
04/07/03	Cholesterol, Total	Abnormal		
04/07/03	GLUCOSE PLASMA			
04/07/03	Electrol			
04/07/03	THYRE LADS			
04/07/03	RPR (MONITOR) W/ REFL TITER			
01/28/03	ELECTROLYTE PANEL			

Making Sense of Clinical Data: Analysis Repository

Practice Analytics: Preemdeon^{**} positioned reports plus ability to create custom queries

Practice Analytics -	[Main]			_ 7 🛛
<u>Surveillance InfoCHARTS</u> Appointments Financial Analysis CMS Graphs	Multi-pass Queries Collections Procedure Analysis CMS Reports	Radiology (RIS) Referrals Demographics Multi-pass Queries	Favorite Fields GL Xfer Aging Public	(RIS)
CAD-01_AntiplateletTherapy CAD-04_ACEInhibitorTherapy DM-02_HbA1c Mgmt Poor Control DM-03_UrineProteinTesting HF-03_WeightMeasurement HF-05_Beta-BlockerTherapy HF-06_ACEInhibitorTherapy PC-02_BloodPressureLevels PC-03_PlanOfCare PC-03_InfluenzaVaccination PC-12_LDLCholesterolLevel				
Admin New Run Ma	Delete			Help Exit

Folder: "CMS Reports", 11 item(s), 0 are public

Database Updated 4/9/03 4/12/2003 7:10 PM CAPS NUM

Example: HbA1c Management Graph

Practice Analytics--Graph [DM02_HbA1c MGMT]

<u>File</u> <u>Help</u>

Example: Diabetic Urine Protein Testing

Practice Analytics - [Graph DM-03_UrineProteinTesting]

<u>File</u> <u>Help</u>

Quality Data Reporting: Nephrology Example

Used with Permission from: David Simon, MD Medical Director Metabolism Associates New Haven, Connecticut

Quality Data Reporting: Nephrology Example

9

The Treatment of End-stage Renal Disease (Dialysis/Transplantation) Is an Enormous Burden on the U.S. Health Care System

End Stage Renal Disease: Scope of the Problem

Medicare spending alone on ESRD care for exceeds 12 billion dollars annually.

Focus has shifted to patients with pre-dialysis chronic kidney in order to decrease progression to ESRD

Nephrology: a focus of CMS Quality Measures

- "The ESRD program has a long history of concern for quality of care. Medicare, the National Institutes of Health, the National Kidney Foundation, the American Society of Nephrology, the Renal Physicians Association and others have actively participated in efforts to develop data systems that support the measurement and improvement of quality.
- The history of quality improvement efforts, the availability of data systems and quality standards, and consensus on opportunities for quality improvement combine to make ESRD a good candidate for possible P4P initiatives. ESRD is, in fact, the focus of a CMS Break-through Initiative in the area of quality."

Capture of Clinical Data: Byproduct of Patient Visits

~	o the hand of the the second						
Lare	Guidelines: Nephrology Clinical Guidelines					🔽 Work Pane	🔲 Due Only
Pri	4 Reminder	Frequency	Status 4	Guideline	Recommended	A Last Recorded	Comments
2	Hemoglobin A1c	q3months	Overdue	Diabetes Control	06/01/2002	03/03/2002	Ordered
2	Hemoglobin	monthly	Due	Epogen Management			
2	Nutritional Assessment	q3months	Due	Nutritional Management			
2	Serum Potassium	weekly	Due	Potassium Management			
2	Serum Calcium	monthly	Due	Calcium Management			
2	Blood Pressure Measurement	q3months	Current	Blood Pressure Control	11/06/2004	08/08/2004	
2	Assessment of Symptom of Chest Pain	q3months	Current	Coronary Artery Disease Screening	10/27/2005	07/29/2005	

Show Guidelines

EHR: Efficient and Informative Patient Care

Chronic Kidney Disease Disease Age Distribution (Metabolism Associates)

Severity of CKD using GFR: Age, Creatinine, Weight

Epogen Patients and Hemoglobin

Hemoglobin

n=177

Blood Pressure Reporting

Summary: Nephrology Quality Data (Metabolism Associates)

- Structured clinical data is being captured as a byproduct of patient care.
- Chronic Kidney Disease (CKD) is focus of quality reporting.
- Quality Measures being captured currently at Metabolism Associates:
 - > Age distribution of CKD
 - > Severity of CKD (via serum creatinine)
 - > Epogen efficacy (via Hemoglobin levels)
 - >Blood Pressure Control (via vital signs)

Quality Reporting in Medical Oncology

Osceola Cancer Center

CMS 2006 Oncology Demonstration Project

- CMS' 2006 demonstration project will gather information relevant to the quality of care for cancer patients.
- Reporting will be associated with physician evaluation and management (E & M) visits.
- 13 target cancers: breast cancer, chronic myelogenous leukemia, colon cancer, esophageal cancer, gastric cancer, head and neck cancer, multiple myeloma, non-Hodgkin's lymphoma, non-small cell/small cell lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, or rectal cancer.
- Participants will receive oncology demonstration payment of \$23.
 - The physician must submit one G-code from each of three categories.

Rapid configuration of EHR to capture G-Codes.

Summary: EHR Strategies for Pay for Performance

- The right EHR system will allow a practice to establish a workflow which assists the physicians in providing efficient patient care while capturing quality data as a *byproduct* of patient visits.
 - The physicians focus on patient care while the EHR captures the necessary information in the background.
- Vital signs, medications, lab results, diagnoses, and clinical findings all play a role in automating quality reporting.
- Once an EHR with structured data capture is adopted by a medical practice, it is straightforward to map specific quality codes (e.g. G-codes) into existing EHR tools.
- Pay for Performance will not be limited to primary care/Adult medicine, but will extend to a broad range of specialties.

Electronic Health Record Strategies for Pay for Performance

James O'Connor MD Director of Clinical Informatics

